Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
atorvastatin calcium, Quantity: 41.44 mg (Equivalent: atorvastatin, Qty 40 mg)
Medis Pharma Pty Ltd
Atorvastatin calcium
Tablet, film coated
Excipient Ingredients: microcrystalline cellulose; povidone; methionine; magnesium stearate; crospovidone; sodium carbonate; mannitol; purified talc; titanium dioxide; hypromellose; macrogol 6000
Oral
30 tablets
(S4) Prescription Only Medicine
An adjunct to diet for the treatment of patients with hypercholesterolaemia. . Prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. . Atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (CHD) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic CHD to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. These effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.
Visual Identification: white oval biconvex tablet with "40" on one side and "A" on reverse.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius
Registered
2012-05-08
Atostat PI Dec 2018 AUSTRALIAN PRODUCT INFORMATION – ATOSTAT® (ATORVASTATIN CALCIUM) 1. NAME OF THE MEDICINE Atorvastatin calcium 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ATOSTAT tablets contain atorvastatin calcium equivalent to 10, 20, and 40 mg atorvastatin. The tablets also contain the following inactive ingredients: Mannitol, Microcrystalline cellulose, Crospovidone, Sodium carbonate anhydrous, Povidone, Methionine, Magnesium stearate, Talc and Opadry 03F28446 White (ARTG 107577). 3. PHARMACEUTICAL FORM ATOSTAT is available in three strengths: 10 mg: white oval biconvex tablet with “10” on one side and “A” on reverse. 20 mg: white oval biconvex tablet with “20” on one side and “A” on reverse. 40 mg: white oval biconvex tablet with “40” on one side and “A” on reverse. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ATOSTAT is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. Prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. ATOSTAT is indicated in hypertensive patients with multiple risk factors for coronary heart disease (CHD) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic CHD (see CLINICAL TRIALS, Prevention of Cardiovascular Disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. These effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. 4.2 DOSE AND METHOD OF ADMINISTRATION Atostat PI Dec 2018 ATOSTAT can be administered within the dosage range of 10–80 mg/day as a single daily dose. ATOSTAT can be taken at any time of the day, with or without food. Therapy should be individualised accord Read the complete document